Role of oral cyclophosphamide in the treatment of giant cell arteritis.

  title={Role of oral cyclophosphamide in the treatment of giant cell arteritis.},
  author={Luca Quartuccio and Marta Maset and Giovanna De Maglio and Elena Pontarini and Martina Fabris and Elisa Mansutti and Laura Mariuzzi and Stefano Pizzolitto and Carlo Alberto Beltrami and Salvatore de Vita},
  volume={51 9},
OBJECTIVE Glucocorticoid (GC)-related adverse events greatly contribute to the outcome in giant cell arteritis (GCA). CYC was investigated as a steroid-sparing agent in GCA. METHODS Nineteen patients treated with CYC were retrospectively analysed. CYC was administered in 15 of the 19 patients after failure of high doses of GC or relapse during medium to high doses of GC, with or without MTX, while CYC was used ab initio in 4 of the 19 patients, all with type 2 diabetes. Follow-up ranged from… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-9 of 9 extracted citations

The Treatment of Giant Cell Arteritis.

Current treatment options in neurology • 2017


Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…